Aptorum Group Limited (NASDAQ:APM) Sees Significant Drop in Short Interest

Aptorum Group Limited (NASDAQ:APM) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 110,800 shares, a decrease of 51.3% from the September 15th total of 227,700 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average daily volume of 9,770,000 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 9,770,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 2.6% of the shares of the company are short sold.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Aptorum Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aptorum Group in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Aptorum Group Trading Up 3.2%

Shares of NASDAQ:APM opened at $1.60 on Tuesday. The stock has a fifty day moving average of $1.90 and a 200-day moving average of $1.36. Aptorum Group has a one year low of $0.46 and a one year high of $7.49.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.